Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Elicio Therapeutics (ELTX) Other Operating Expenses (2020 - 2024)

Elicio Therapeutics filings provide 4 years of Other Operating Expenses readings, the most recent being $105000.0 for Q4 2023.

  • On a quarterly basis, Other Operating Expenses rose 103.34% to $105000.0 in Q4 2023 year-over-year; TTM through Sep 2023 was -$3.3 million, a 37.52% decrease, with the full-year FY2024 number at $3000.0, changed N/A from a year prior.
  • Other Operating Expenses hit $105000.0 in Q4 2023 for Elicio Therapeutics, up from -$105000.0 in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $433000.0 in Q4 2021 to a low of -$3.1 million in Q4 2022.
  • Median Other Operating Expenses over the past 4 years was $126000.0 (2020), compared with a mean of -$480000.0.
  • Biggest five-year swings in Other Operating Expenses: surged 243.65% in 2021 and later tumbled 826.56% in 2022.
  • Elicio Therapeutics' Other Operating Expenses stood at $126000.0 in 2020, then surged by 243.65% to $433000.0 in 2021, then tumbled by 826.56% to -$3.1 million in 2022, then skyrocketed by 103.34% to $105000.0 in 2023.
  • The last three reported values for Other Operating Expenses were $105000.0 (Q4 2023), -$105000.0 (Q3 2023), and -$3.1 million (Q4 2022) per Business Quant data.